BridgeMD
New treatment option for Acute Upper Gastrointestinal Bleeding
Official title Timing of Endoscopy in Cirrhotic Patients with Acute Variceal Bleeding
ClinicalTrials.gov ID: NCT06031402
What this study is testing
- What it's testing
- Endoscopy is important for the diagnosis and treatment of acute upper gastrointestinal bleeding (AUGIB), especially acute variceal bleeding (AVB), in patients with liver cirrhosis. However, the optimal timing of endoscopy remains controversial, primarily because the currently available evidence is of poor quality, and the definition of early endoscopy is also very heterogeneous among studies.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- patients with AUGIB which is highly suspected to be caused by gastroesophageal variceal rupture;
- patients with a diagnosis of liver cirrhosis based on imaging and pathology;
- patients and/or their relatives who sign informed consents;
- patients' age ≥18 years.
You likely can't join if
- patients who have undergone endoscopy at other hospitals before admissions;
- patients' hemodynamics are unstable after resuscitation;
- patients with severe cardiovascular or cerebrovascular diseases or renal injury;
- patients who have taken anticoagulants or antiplatelet drugs within 2 weeks before admissions, or are diagnosed with severe hematological diseases;
- patients with human immunodeficiency virus or other acquired or congenital immune deficiency diseases;
- patients with mental illness;
See the full eligibility criteria
- patients with AUGIB which is highly suspected to be caused by gastroesophageal variceal rupture;
- patients with a diagnosis of liver cirrhosis based on imaging and pathology;
- patients and/or their relatives who sign informed consents;
- patients' age ≥18 years.
- patients who have undergone endoscopy at other hospitals before admissions;
- patients' hemodynamics are unstable after resuscitation;
- patients with severe cardiovascular or cerebrovascular diseases or renal injury;
- patients who have taken anticoagulants or antiplatelet drugs within 2 weeks before admissions, or are diagnosed with severe hematological diseases;
- patients with human immunodeficiency virus or other acquired or congenital immune deficiency diseases;
- patients with mental illness;
- pregnancy.
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.